OmniAb SPAC Presentation Deck

SUGEMALIMAB APPROVED THE SECOND APPROVED OMNIRAT-DERIVED ANTIBODY ● 1361 基石药业 CSTONE PHARMACEUTICALS 34 On December 21, 2021, CStone announced approval in China for Cejemly® (sugemalimab) Fully-human, full length anti-PD-L1 monoclonal, said to mirror the natural G-type immunoglobulin 4 (IgG4), which reduces immunogenicity risks and potential toxicity, approved as part of first-line treatment for metastatic nonsquamous NSCLC Touted by CStone as "first and only anti-PD-L1 approved for first-line treatment in metastatic nonsquamous NSCLC anywhere in the world" CStone also has an NDA pending for Cejemly® for Stage III NSCLC Pfizer responsible for commercializing in China via 2020 strategic collaboration EQRx licensed exclusive rights to sugemalimab for development / commercialization outside of China, targeting filings by year-end OmniAb

View entire presentation